Stock Quotes in this Article: APPY, ATHX, DVAX, TSRX, NAVB

WINDERMERE, Fla. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility. Stocks that are making big-percentage moves either up or down are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

>>5 Hated Earnings Stocks Poised to Pop

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining technical indicators with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that amade large moves to the upside on Tuesday.

>>5 Stocks Setting Up to Break Out

Venaxis

Venaxis (APPY) is a biomedical company focused on obtaining U.S. FDA clearance for its lead product, AppyScore, a blood-based test designed to help physicians manage patients who suffer from abdominal pain and acute appendicitis. This stock closed up 9.5% to $2.18 on Tuesday.

Tuesday's Range: $1.97-$2.29

52-Week Range: $1.18-$6.54

Volume: 180,000

Three-Month Average Volume: 238,445

From a technical perspective, APPY ripped higher here right off some previous support levels around $2 with below-average volume. This move has pushed APPY right below its 50-day moving average of $2.30 and within range of triggering a near-term breakout trade. That trade will hit if APPY manages to take out its 50-day at $2.30 and its 200-day at $2.46 with high volume.

Traders should now look for long-biased trades in APPY as long as it’s trending $2 and then once it sustains a move or close above those breakout levels with volume that hits near or above 238,445 shares. If that breakout triggers soon, then APPY will set up to re-test or possibly take out its next major overhead resistance levels $2.80 to $2.99.

Navidea Biopharmaceuticals

Navidea Biopharmaceuticals (NAVB) is a biomedical company engaged in the development and commercialization of innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of physicians. This stock closed up 4% to $3.10 on Tuesday.

Tuesday's Range: $2.95-$3.11

52-Week Range: $2.14-$4.77

Volume: 904,000

Three-Month Average Volume: 634,622

From a technical perspective, NAVB ripped higher here right off some near-term support at $2.90 with above-average volume. This move is quickly pushing shares of NAVB within range of triggering a near-term breakout trade. That trade will hit if NAVB manages to clear its 200-day moving average of $3.13 with high volume.

Traders should now look for long-biased trades in NAVB as long as it’s trending above some key near-term support at $2.90 and then once it sustains a move or close above its 200-day at $3.13 with volume that hits near or above 634,622 shares. If that breakout triggers soon, then NAVB will set up to re-test or possibly take out its next major overhead resistance level at $3.37. Any high-volume move above $3.37 will then put NAVB within range of tagging its next major overhead resistance levels at $3.80 to $4.10.

Trius Therapeutics

Trius Therapeutics (TSRX) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. This stock closed up 7.4% to $5.28 on Tuesday.

Tuesday's Range: $4.96-$5.29

52-Week Range: $4.41-$6.49

Volume: 1.29 million

Three-Month Average Volume: 382,453

From a technical perspective, TSRX soared higher here right off its 50-day moving average of $4.97 with monster upside volume. This move filled a previous gap down level from a few weeks ago that started at $5.20. Shares of TSRX are now quickly moving within range of triggering a near-term breakout trade. That trade will hit if TSRX manages to clear its 200-day at $5.37 and then once it takes out more resistance at $5.60 with high volume.

Traders should now look for long-biased trades in TSRX as long as it’s trending above its 50-day at $4.97 and then once it sustains a move or close above those breakout levels with volume that hits near or above 382,453 shares. If that breakout hits soon, then TSRX will set up to re-test or possibly take out its next major overhead resistance levels at $5.90 to $5.93. Any move above those levels will then put $6.20 to $6.46 into focus for shares of TSRX.

Dynavax Technologies

Dynavax Technologies (DVAX), a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases. This stock closed up 3.6% to $3.15 on Tuesday.

Tuesday's Range: $3.01-$3.21

52-Week Range: $2.22-$5.34

Volume: 6.07 million

Three-Month Average Volume: 3.76 million

From a technical perspective, DVAX spiked higher here right off its 50-day moving average of $2.92 with massive upside volume. This move is quickly pushing shares of DVAX within range of triggering a major breakout trade. That trade will hit if DVAX manages to take out some near-term overhead resistance at $3.39 with high volume.

Traders should now look for long-biased trades in DVAX as long as it’s trending above its 50-day at $2.92, and then once it sustains a move or close above $3.39 with volume that hits near or above 3.76 million shares. If that breakout triggers soon, then DVAX will set up to re-fill some of its gap down zone from last November that started around $4.75. Some possible upside targets if DVAX gets into that gap are its 200-day at $3.90 to $4.25.

Athersys

Athersys (ATHX) is a biopharmaceutical company focused in the field of regenerative medicine. This stock closed up 3.8% to $1.34 on Tuesday.

Tuesday's Range: $1.30-$1.37

52-Week Range: $0.95-$2.33

Volume: 1.19 million

Three-Month Average Volume: 411,960

From a technical perspective, ATHX spiked higher here back above its 200-day moving average of $1.33 with monster upside volume. This stock has been uptrending strong for the last three months, with shares soaring from its low of 95 cents to its recent high of $1.37. During that move, shares of ATHX have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed ATHX within range of triggering a near-term breakout trade. That trade will hit if ATHX manages to take out some near-term overhead resistance levels at $1.37 to $1.47 and then once it clears more resistance at $1.60 with high volume.

Traders should now look for long-biased trades in ATHX as long as it’s trending above some key near-term support levels at $1.22 to $1.15, and then once it sustains a move or close above those breakout levels with volume that hits near or above 411,960 shares. If that breakout triggers soon, then ATHX will set up to re-test or possibly take out its next major overhead resistance levels a $1.75 to $1.80. Any high-volume move above $1.80 will then put $2.14 to $2.33 into focus for shares of ATHX.

To see more stocks that are making notable moves higher, check out the Stocks Under $10 Moving Higher portfolio on Stockpickr.

-- Written by Roberto Pedone in Winderemere, Fla.

RELATED LINKS:

>>5 Bottoming Stocks Starting to Signal a Buy
>>5 Rocket Stocks to Buy This Week

>>5 Stocks That Want to Pay You More This Quarter

Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Windermere, Fla., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including CNBC.com and Forbes.com. You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.